Le Min F Stephen Hodi
10.1158/2326-6066.CIR-13-0146
Cancer Immunol Res
2014 Jan;2(1):15-8.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/24778161/
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Melanoma / drug therapy Melanoma / pathology Mucous Membrane / pathology
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Melanoma / drug therapy Melanoma / pathology Mucous Membrane / pathology Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal, Humanized Antineoplastic Agents / pharmacology CTLA-4 Antigen / antagonists & inhibitors Humans Hypothyroidism / diagnosis Hypothyroidism / etiology Ipilimumab Male Middle Aged Programmed Cell Death 1 Receptor / antagonists & inhibitors Rhabdomyolysis / diagnosis Rhabdomyolysis / etiology Treatment Outcome Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents CTLA-4 Antigen Ipilimumab Programmed Cell Death 1 Receptor pembrolizumab
PMC4006358
24778161
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis
2014